Nationwide Children's Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

100

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

12 drugs in development

Phase 35

Phase 23

Phase 15

By Therapeutic Area

top 1

Oncology

12100%

R&D Momentum

70/100

Pipeline Velocity

39/100

Trial Completion Rate

63/100

Pipeline Concentration

100/100

Pipeline Freshness

67/100

Activity

Recent Activity

Last 14 days

Sep 17, 2026

Active, not recruiting

A Phase I/II Safety Lead in Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Irinotecan, Temozolomide, and Dinutuximab in Patients With Relapsed or Refractory Neuroblastoma: The Allo - STING Trial

Sep 10, 2026

Enrolling by invitation

Train-of-four Monitoring Using the TetraGraph Electromyographic Neuromuscular Transmission Monitor to Evaluate Onset and Recovery Times of a Single Bolus Dose of Rocuronium

Sep 9, 2026

Recruiting

Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma

Earlier

Sep 2, 2026TrialTransauricular Neurostimulation for Irritable Bowel Syndrome

Aug 29, 2026TrialParent-Implemented Oral Nutrition, Eating, and Esophageal Reflexes Reintegration Program Using Novel Aerodigestive Stimulation in Gastrostomy Risk Infants: RCT on Clinical and Mechanistic Outcomes

Aug 28, 2026TrialPilot Feasibility Clinical Trial of Virtual Reality for Pain Management During Repeated Pediatric Laser Procedures

Aug 25, 2026TrialVirtual Reality Implementation for Pain and Anxiety Management During Intra-articular Glucocorticoid Injections in a Pediatric Rheumatology Clinic

Aug 25, 2026TrialPhase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

2 more events

Aug 22, 2026TrialApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness

Aug 20, 2026TrialEstablishing Clinical Trial Readiness for Children 0-5 Years With Congenital Muscular Dystrophy Secondary to LAMA2 Mutations (READY CMD LAMA2)

Details